- ACY-775
-
- $43.00 / 5mg
-
2026-04-22
- CAS:1375466-18-4
- Min. Order:
- Purity: 98.83%
- Supply Ability: 10g
|
| | 2-[1-(3-Fluoro-phenyl)-cyclohexylamino]-pyrimidine-5-carboxylic acid hydroxyamide Basic information |
| | 2-[1-(3-Fluoro-phenyl)-cyclohexylamino]-pyrimidine-5-carboxylic acid hydroxyamide Chemical Properties |
| density | 1.342±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | DMSO:35.33(Max Conc. mg/mL);106.94(Max Conc. mM)
DMF:20.0(Max Conc. mg/mL);60.54(Max Conc. mM)
DMF:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.61(Max Conc. mM)
Ethanol:34.5(Max Conc. mg/mL);104.43(Max Conc. mM) | | form | A solid | | pka | 7.74±0.10(Predicted) | | color | White to off-white |
| | 2-[1-(3-Fluoro-phenyl)-cyclohexylamino]-pyrimidine-5-carboxylic acid hydroxyamide Usage And Synthesis |
| Uses | ACY-775 is a novel histone deacetylase 6-selective (HDAC6) inhibitor with antidepressant and pro-cognitive properties. ACY-775 inhibits HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs. | | in vivo | Biodistribution profiles of ACY-738, ACY-775, and tubastatin A are examined after acute dosing at 5 or 50mg/kg over 2h. At t=30min after acute 50mg/kg injection, respective plasma levels of ACY-738 and ACY-775 are 515ng/mL (1.9μM) and 1359ng/mL (4.1μM). Elimination from plasma is rapid, with plasmatic half-life of 12min and concentration below 10ng/mL after 2h. Nevertheless, areas under concentration time curves for brain and plasm calculated over 2h for both ACY-738 and ACY-775 lead to ratios >1. When ACY-738 (5mg/kg) or ACY-775 (50mg/kg) are administered repeatedly in wild-type mice at 24h, 4h, and 30min before killing, significant increases in α-tubulin acetylation are observed in all tested brain regions[2]. | | IC 50 | HDAC6: 7.5 nM (IC50); HDAC1: 2123 nM (IC50); HDAC2: 2570 nM (IC50); HDAC3: 11223 nM (IC50) |
| | 2-[1-(3-Fluoro-phenyl)-cyclohexylamino]-pyrimidine-5-carboxylic acid hydroxyamide Preparation Products And Raw materials |
|